Previously treated cases tested for RR-/MDR-TB in South-East Asia (WHO region)
South-East Asia (WHO region): Previously treated cases tested for RR-/MDR-TB was 83.0% in 2024. ◆ Volatile
Previously treated cases tested for RR-/MDR-TB in South-East Asia (WHO region), 2005–2024
Source: World Health Organization, Global Health Observatory.
Analysis
In 2024, previously treated cases tested for rr-/mdr-tb in South-East Asia (WHO region) stood at 83.0%.
That represents a change of up 2.5% on the previous year and up 25.8% over ten years.
Over the whole period, previously treated cases tested for rr-/mdr-tb in South-East Asia (WHO region) peaked at 89.0% in 2020 and was at its lowest, 0.2%, in 2005.
The series is highly variable year to year, so single readings are best treated with caution.
Previously treated cases tested for RR-/MDR-TB in South-East Asia (WHO region), year by year
| Year | Value | Change |
|---|---|---|
| 2005 | 0.2% | — |
| 2006 | 0.4% | +141.2% |
| 2007 | 0.4% | +2.4% |
| 2008 | 0.9% | +104.8% |
| 2009 | 1.6% | +86.0% |
| 2010 | 0.3% | -82.5% |
| 2011 | 0.4% | +28.6% |
| 2012 | 0.8% | +116.7% |
| 2013 | 4.8% | +515.4% |
| 2014 | 66.0% | +1275.0% |
| 2015 | 56.0% | -15.2% |
| 2016 | 66.0% | +17.9% |
| 2017 | 80.0% | +21.2% |
| 2018 | 64.0% | -20.0% |
| 2019 | 78.0% | +21.9% |
| 2020 | 89.0% | +14.1% |
| 2021 | 68.0% | -23.6% |
| 2022 | 77.0% | +13.2% |
| 2023 | 81.0% | +5.2% |
| 2024 | 83.0% | +2.5% |
Biggest year-on-year movements
Years where Previously treated cases tested for RR-/MDR-TB in South-East Asia (WHO region) changed far more than this series normally does. A large move can be a real event or a change in how the figure was measured — the source note below says who published it.
| Year | Change | From | To |
|---|---|---|---|
| 2014 | +1275.0% | 4.8% | 66.0% |
| 2013 | +515.4% | 0.8% | 4.8% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 0.7% | 0.2% | 1.6% | 5 |
| 2010s | 41.6% | 0.3% | 80.0% | 10 |
| 2020s | 79.6% | 68.0% | 89.0% | 5 |
More health data for South-East Asia (WHO region)
- Pertussis - number of reported cases, gaps filled 2,449 (2025)
- Total tetanus - number of reported cases, gaps filled 164 (2025)
- Neonatal tetanus - number of reported cases, gaps filled 84 (2025)
- Measles - number of reported cases, gaps filled 19,075 (2025)
- Diphtheria - number of reported cases, gaps filled 3,416 (2025)
- Number of under-five deaths, annual growth rate -4.64 % change on previous year (2024)
- Number of neonatal deaths, annual growth rate -4.57 % change on previous year (2024)
- Number of infant deaths, annual growth rate -4.21 % change on previous year (2024)
- Measles - number of reported cases, annual growth rate -30.44 % change on previous year (2025)
- Pertussis - number of reported cases, annual growth rate -67.98 % change on previous year (2025)
Frequently asked questions
- What is previously treated cases tested for rr-/mdr-tb in South-East Asia (WHO region)?
- Previously treated cases tested for rr-/mdr-tb in South-East Asia (WHO region) was 83.0% in 2024, according to World Health Organization, Global Health Observatory.
- What is the highest previously treated cases tested for rr-/mdr-tb recorded in South-East Asia (WHO region)?
- The highest recorded value was 89.0% in 2020.
- What is the lowest previously treated cases tested for rr-/mdr-tb recorded in South-East Asia (WHO region)?
- The lowest recorded value was 0.2% in 2005.
- How does South-East Asia (WHO region) rank for previously treated cases tested for rr-/mdr-tb?
- South-East Asia (WHO region) ranks 5th out of 11 groups with data for 2024.
- Is previously treated cases tested for rr-/mdr-tb rising or falling in South-East Asia (WHO region)?
- Over the last ten years it is up 25.8%. The long-run trend across the full record is volatile.
- Where does this South-East Asia (WHO region) data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of Previously treated cases tested for RR-/MDR-TB (%). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 20 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).